Development of a Group A Meningococcal Conjugate Vaccine, MenAfriVac™
Group A meningococcal disease has been an important public health problem in sub-Saharan Africa for over a century. From 2003 to 2009 a monovalent group A conjugate vaccine, MenAfriVac™, was developed through an innovative public/private partnership. This article, published in Human Vaccines & Immunotherapeutics, summarizes the laboratory and clinical studies leading to prequalification of MenAfriVac™. The vaccine was introduced in Burkina Faso, Mali, and Niger in December 2010, and the 2011 epidemic season ended with no reported cases of group A meningitis in vaccinated individuals. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Frasch C, Preziosi M-P, LaForce FM
Visit web page (English)
(Located at www.landesbioscience.com)
Citation: Frasch C, Preziosi M-P, LaForce FM. Development of a Group A Meningococcal Conjugate Vaccine, MenAfriVac™. Human Vaccines & Immunotherapeutics. 2012;8(6):Early Online Publication.